Navigation Links
DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology
Date:3/11/2009

SAN DIEGO, March 11 /PRNewswire/ -- Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces that DSM Biomedical obtained an exclusive world-wide license for a unique drug & biologic delivery system developed by MediVas LLC, a San Diego based biomedical company. Integrated into DSM's Trancerta(R) Drug Delivery platform, this will open up a broad range of opportunities for next generation drug delivery. DSM's activities in this field are a perfect illustration of the way DSM is leveraging its competences in Materials Sciences into Life Sciences applications.

MediVas' technology for the delivery of biologics and drugs is based on a next generation set of polymers exclusively licensed from Cornell University. Generated from research both at Cornell and at MediVas, the company has an IP portfolio containing over 60 issued or pending US patents. The polymers are biodegradable, biocompatible and bioabsorbable. Furthermore they are non-inflammatory and allow greater control over the rate and duration of release of their therapeutic payload.

The technology can be used with a diverse group of drug candidates, from proteins, peptides and nucleic acids to small molecule drugs, thus expanding the possible application areas of DSM's Trancerta(R) platform. The license DSM obtained applies for the development of drug delivery systems aimed at treating ophthalmic, (cardio)vascular, musculoskeletal diseases and at providing general pain relief. MediVas will focus its development efforts on nanoparticle based therapies in oncology, immunology and on the delivery of nucleic acids.

"Through this deal we bring in the first biodegradable polymer into DSM's Biomedical portfolio, which significantly enhances our materials competences. This will help us realize our ambition to build a portfolio of drug delivery systems tailored at the specific needs of the health industry. MediVas' technology is already proven in two clinical studies which should allow us to accelerate the commercialization of our drug delivery technologies in partnerships with Pharma, Biotech and Medical Device Companies," said Steve Hartig, President of DSM Biomedical.

"The license with DSM is an ideal strategic fit which will accelerate the efforts of MediVas to commercialize our novel biopolymer technology. DSM's extensive materials expertise and broad industrial capabilities provide MediVas with a valuable partner in advancing our respective projects through the clinic. We look forward to working closely with DSM in applying our technology to meet the rapidly increasing demand for improved drug and biologic delivery systems," commented Kenneth Carpenter, Chairman and CEO of MediVas.

DSM - the Life Sciences and Materials Sciences Company

Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM has annual net sales of EUR 9.3 billion and employs some 23,500 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com

DSM Biomedical

DSM Biomedical develops novel materials-based solutions to meet the present and future needs of the medical device and pharmaceutical industries. Its portfolio includes coatings, drug delivery platforms and a wide range of biomedical materials for use in short and long term implantable medical devices. In drug delivery, DSM employs the Trancerta(TM) Drug Delivery approach which is based on DSM's core strengths in polymers combined with its extensive in-house library of synthesis methods, formulation and processing techniques. DSM's current biomedical portfolio also includes ComfortCoat(TM) hydrophilic and antimicrobial coating technology for catheters, guidewires and stent delivery systems and Dyneema Purity(R), a high performance polyethylene fiber technology, which has been developed specifically for use in medical applications, such as orthopedic implants. Last year the company acquired the Polymer Technology Group, a market leader in the field of biomedical polymers. Furthermore, a research and development program specifically aimed at extending DSM's material portfolio for the orthopedic industry has been started. For more information, visit www.dsmbiomedical.com.

MediVas LLC

Using its proprietary family of biodegradable and biocompatible polymers, MediVas has developed unique platforms for the delivery of biologics. MediVas is utilizing its novel polymer technology in collaboration with some of the world's largest pharmaceutical companies, as well as on its own internal product development efforts, to create groundbreaking medical advancements. By combining therapeutic proteins and other biologics with a MediVas polymer, delivery routes that were previously unattainable, such as oral, intranasal, inhaled or subcutaneous injection, can now be achieved. With these routes of delivery then available, MediVas' delivery system can make the administration of the biologic more convenient, more efficacious and safer, leading to higher patient compliance and overall better health. For more information visit www.medivas.com or contact Joseph Dowling at +1 (858) 622-2005.


'/>"/>
SOURCE MediVas LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany
2. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
3. First Molecular Tem-PCR Test to Identify Multiple Forms of Staph and MRSA Obtains CLIA Certificate
4. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
5. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
6. The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
7. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
10. Stem Cell Sciences Announces the Creation of the Worlds First Authentic Rat Embryonic Stem Cells from its Exclusively Licensed Technology
11. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... PUNE, India , January 24, 2017 /PRNewswire/ ... Market Research, titled, "Cold Chain Logistics Market by Application ... Frozen Dessert, Meat, Fish & Sea Food, Drugs & ... Forecasts, 2014-2022," projects that the global cold chain logistics ... growing at a CAGR of 16% (2016 to 2022). ...
(Date:1/24/2017)... , Jan. 24, 2017 Regeneron Pharmaceuticals, Inc. ... Public today recognized 40 finalists in the Regeneron Science ... and math competition for high school seniors. Finalists were ... of their research projects. The finalists will ... from March 9-15 to undergo a rigorous judging process ...
(Date:1/24/2017)... 24, 2017 Research and Markets has announced ... Trends - Product, Material - Forecast to 2025" report to ... ... a CAGR of around 5.4% over the next decade to reach ... trends that the market is witnessing include 3D medical printing is ...
Breaking Medicine Technology:
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... This Saturday, ... & magic, plus a very special performance by Alabama Symphony Orchestra musicians Yifan Zhou, ... their specialties, such as dim sum, and exhibitors offer a look at Chinese games, ...
(Date:1/24/2017)... ... 2017 , ... Inspiration, Community & Mentorship – Top Students ... Fordham Institute’s High Stakes for High Achievers offer recommendations for how ... high-achieving students as a subgroup and reporting their results separately. Top students and ...
(Date:1/24/2017)... Pass, OR (PRWEB) , ... January 24, 2017 ... ... Gerald H. Pollack, Ph.D., http://www.faculty.washington.edu/ghp , Sharon Kleyne, the nation’s foremost ... of Water, Global Climate Change and Your Health on Voice America, once again ...
(Date:1/24/2017)... Scottsdale, AZ (PRWEB) , ... January 24, 2017 , ... ... than 30 lives in the last month. Yellow fever is primarily spread through contact ... the health community’s focus on how to prevent its spread. , According to multiple ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... to topics like finances, friendship, marriage, leadership, gossip, prostitution, adultery, anger, and common ... Publishing authors, Dr. Judith Coats and Dr. David Coats. In September of 1983, ...
Breaking Medicine News(10 mins):